| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $539 ) |
| | 2023 | 2020 | SAINT JOHN'S CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2312 | LOS ANGELES | USA | R21AG061494 | Mobile Technology-Based Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults with Mild Cognitive Impairment | 000 | 2 | NIH | 11/23/2022 | $539 |
|
| Issue Date FY: 2022 ( Subtotal = -$35,528 ) |
| | 2022 | 2020 | SAINT JOHN'S CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2312 | LOS ANGELES | USA | R21AG061494 | Mobile Technology-Based Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults with Mild Cognitive Impairment | 001 | 2 | NIH | 4/12/2022 | -$539 |
| | 2022 | 2020 | SAINT JOHN'S CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2312 | LOS ANGELES | USA | R21AG061494 | Mobile Technology-Based Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults with Mild Cognitive Impairment | 000 | 2 | NIH | 11/16/2021 | $0 |
| | 2022 | 2017 | SAINT JOHN'S CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2312 | LOS ANGELES | USA | R01FD005077 | Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma | 000 | 3 | FDA | 6/21/2022 | -$34,989 |
|
| Issue Date FY: 2020 ( Subtotal = $198,822 ) |
| | 2020 | 2020 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R21AG061494 | Mobile Technology-Based Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults with Mild Cognitive Impairment | 000 | 2 | NIH | 12/2/2019 | $184,500 |
| | 2020 | 2020 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R21AG061494 | Mobile Technology-Based Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults with Mild Cognitive Impairment | 001 | 2 | NIH | 1/23/2020 | $20,500 |
| | 2020 | 2018 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA189163 | Multicenter Selective Lymphadenectomy Trial (MSLT II) in Melanoma | 000 | 5 | NIH | 2/18/2020 | $0 |
| | 2020 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA171767 | Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment | 000 | 5 | NIH | 12/18/2019 | -$6,178 |
| | 2020 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01FD005077 | Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma | 001 | 3 | FDA | 6/15/2020 | $0 |
| | 2020 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01FD005077 | Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma | 002 | 3 | FDA | 9/3/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $142,866 ) |
| | 2019 | 2019 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R21AG061494 | Mobile Technology-Based Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults with Mild Cognitive Impairment | 001 | 1 | NIH | 7/1/2019 | $0 |
| | 2019 | 2019 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R21AG061494 | Mobile Technology-Based Simultaneous Aerobic Exercise and Memory Training Intervention for Older Adults with Mild Cognitive Impairment | 000 | 1 | NIH | 2/26/2019 | $246,000 |
| | 2019 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 000 | 5 | NIH | 7/1/2019 | -$103,134 |
|
| Issue Date FY: 2018 ( Subtotal = $856,874 ) |
| | 2018 | 2018 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA189163 | Multicenter Selective Lymphadenectomy Trial (MSLT II) in Melanoma | 000 | 5 | NIH | 8/14/2018 | $1,372,351 |
| | 2018 | 2013 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | P01CA029605 | New Approaches to Surgical Oncology | 000 | 32 | NIH | 3/29/2018 | -$515,477 |
|
| Issue Date FY: 2017 ( Subtotal = $2,567,978 ) |
| | 2017 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 000 | 5 | NIH | 3/3/2017 | $344,180 |
| | 2017 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA171767 | Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment | 001 | 5 | NIH | 6/7/2017 | $38,243 |
| | 2017 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA171767 | Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment | 000 | 5 | NIH | 3/30/2017 | $344,180 |
| | 2017 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01FD005077 | Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma | 000 | 3 | FDA | 3/30/2017 | $296,167 |
| | 2017 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 001 | 5 | NIH | 6/7/2017 | $38,243 |
| | 2017 | 2017 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA189163 | Multicenter Selective Lymphadenectomy Trial (MSLT II) in Melanoma | 000 | 4 | NIH | 8/15/2017 | $1,507,063 |
| | 2017 | 2015 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BLVD | SANTA MONICA | CA | 90404-2302 | LOS ANGELES | USA | R01CA151610 | The Role of FOXCI in Basal-like Breast Cancer | 000 | 5 | NIH | 3/29/2017 | -$98 |
|
| Issue Date FY: 2016 ( Subtotal = $2,846,960 ) |
| | 2016 | 2016 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA189163 | Multicenter Selective Lymphadenectomy Trial (MSLT II) in Melanoma | 000 | 3 | NIH | 8/10/2016 | $1,682,114 |
| | 2016 | 2016 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA171767 | Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment | 000 | 4 | NIH | 5/10/2016 | $382,423 |
| | 2016 | 2016 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 000 | 4 | NIH | 2/17/2016 | $382,423 |
| | 2016 | 2016 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01FD005077 | Phase 2 Study of Vascular-Targeted Prodrug (G-202) for the Treatment of Recurrent Glioblastoma | 000 | 2 | FDA | 4/12/2016 | $400,000 |
|
| Issue Date FY: 2015 ( Subtotal = $2,533,979 ) |
| | 2015 | 2015 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 000 | 3 | NIH | 4/1/2015 | $382,423 |
| | 2015 | 2015 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA171767 | Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment | 000 | 3 | NIH | 3/19/2015 | $382,423 |
| | 2015 | 2015 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA189163 | Multicenter Selective Lymphadenectomy Trial (MSLT II) in Melanoma | 000 | 2 | NIH | 8/28/2015 | $1,769,133 |
|
| Issue Date FY: 2014 ( Subtotal = $2,912,814 ) |
| | 2014 | 2014 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01AR059126 | Mechanisms of Innate and Acquired Host Defense and Tissue Injury in Skin | 000 | 6 | NIH | 7/2/2014 | $390,126 |
| | 2014 | 2014 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA171767 | Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment | 000 | 2 | NIH | 3/28/2014 | $370,950 |
| | 2014 | 2014 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 001 | 2 | NIH | 5/2/2014 | $26,770 |
| | 2014 | 2014 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 000 | 2 | NIH | 3/5/2014 | $344,180 |
| | 2014 | 2014 | JOHN WAYNE CANCER INSTITUTE | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA189163 | Multicenter Selective Lymphadenectomy Trial (MSLT II) in Melanoma | 000 | 1 | NIH | 9/23/2014 | $1,780,788 |
|
| Issue Date FY: 2013 ( Subtotal = $6,914,603 ) |
| | 2013 | 2013 | JOHN WAYNE INSTITUTE FOR CANCER TREATMENT & RSCH | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 001 | 1 | NIH | 6/28/2013 | $95,606 |
| | 2013 | 2013 | JOHN WAYNE INSTITUTE FOR CANCER TREATMENT & RSCH | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA167967 | Identification of Melanoma Brain Metastasis Tumor Biomarkers | 000 | 1 | NIH | 2/20/2013 | $286,817 |
| | 2013 | 2013 | JOHN WAYNE INSTITUTE FOR CANCER TREATMENT & RSCH | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA171767 | Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment | 001 | 1 | NIH | 7/1/2013 | $95,606 |
| | 2013 | 2013 | JOHN WAYNE INSTITUTE FOR CANCER TREATMENT & RSCH | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01CA171767 | Predictive Epigenomic Biomarkers In Rectal Cancer Patients Receiving Treatment | 000 | 1 | NIH | 3/1/2013 | $286,817 |
| | 2013 | 2013 | JOHN WAYNE INSTITUTE FOR CANCER TREATMENT & RSCH | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | R01AR059126 | Mechanisms of Innate and Acquired Host Defense and Tissue Injury in Skin | 000 | 5 | NIH | 5/31/2013 | $378,184 |
| | 2013 | 2013 | JOHN WAYNE INSTITUTE FOR CANCER TREATMENT & RSCH | 2200 SANTA MONICA BOULEVARD | SANTA MONICA | CA | 90404 | LOS ANGELES | USA | P01CA029605 | New Approaches to Surgical Oncology | 000 | 32 | NIH | 8/16/2013 | $5,771,573 |
|
|
